Pharma Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cell Genesys
Cell Genesys recaps two presentations from 2006 ASCO Annual Meeting
July 4th, 2006
Cell Genesys, Inc. (CEGE) provided a recap of clinical data reports from two GVAX cancer immunotherapy programs that were presented at the 2006 American Society of Clinical Oncology (ASCO) Annual Meeting in Atlanta, Georgia. In the first oral presentation entitled, "A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with a fully human anti-CTLA-4 antibody (MDX-010, ipilimumab) in patients with metastatic hormone-refractory prostate cancer (HRPC)," Cell Genesys and collaborator, Medarex, Inc., presented encouraging data from a Phase 1 clinical trial of the company's' GVAX immunotherapy for prostate cancer,...
Source: Pharma Law Weekly (2006-07-04)
|
